ROCKVILLE, Md., Sept. 26 /PRNewswire/ -- MacroGenics, Inc. announced today that Mr. Jeffrey H. Buchalter has been elected as Chairman of the company's Board of Directors. With more than 20 years of experience in product development and commercialization in the pharmaceutical and biotechnology industry, Mr. Buchalter is well poised to work with the management team at MacroGenics as the company matures toward commercializing its pipeline.
"We are honored that Mr. Buchalter, an established leader in the biotechnology and pharmaceutical industry, has joined the MacroGenics Board of Directors as Chairman. His proven skills in building and transitioning research and development-based organizations into commercial enterprises will be a tremendous asset to MacroGenics," commented Scott Koenig, M.D., Ph.D., President and CEO.
"I am excited to have an opportunity to work closely with such a talented management team and esteemed group of investors and directors at MacroGenics," said Mr. Buchalter. "The company has done a terrific job in creating one of the best programs in monoclonal antibody therapeutics with its rich pipeline, platforms, and product development capabilities."
Mr. Buchalter currently serves as President, CEO and Chairman of the
Board of Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN), a biopharmaceutical
company dedicated to the development and commercialization of therapeutics
for cancer and other life-threatening diseases. Prior to joining Enzon, Mr.
Buchalter was President and Chief Executive Officer of ILEX Oncology, Inc.,
where he led the company's evolution from a contract research organization
to a product- driven pharmaceutical company, with a high quality oncology
franchise and established
|SOURCE MacroGenics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved